ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Corona Remedies reported robust Q1 FY27 results with 21.9% revenue growth and 33.5% EBITDA growth. Strategy focuses on chronic therapies and scaling brand portfolios.
Corona Remedies reported strong Q1FY27 performance with 21.9% revenue growth and 33.5% EBITDA growth, driven by its strategic shift towards chronic therapies which now contribute ~73.4% of revenue.
Corona Remedies reported strong FY26 results, outperforming industry growth via specialty chronic segments and strategic acquisitions like Wokadine and the Bayer portfolio.
CORONA Remedies reported 17.3% FY26 revenue growth to ₹1,403.2 Cr, driven by chronic therapy focus and strategic acquisitions like Wokadine. Company maintain's 20.9% EBITDA margins.